Immunocore’s bispecific lands speedy review with FDA, EMA; Low-profile gene therapy player grabs $30M

UK TCR-focused biotech Immunocore announced that it scored a priority review with the FDA for lead drug tebentafusp.

The bispecific already boasts a breakthrough therapy designation thanks to positive Phase III data. The priority review shaves four months off the regular 10-month process, leading...

Click to view original post